

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-000366

Date: 25/10/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000, please see response below.

Please note for question 2 only patients who were new to question 1 were counted.

Questions 1 and 2, Ranibizumab is grouped together as it cannot be separated into the specified categories.

1. For the 4 months from May to August 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept -668

Bevacizumab -0

Brolucizumab -13

Dexamethasone -52

Faricimab -580

Ranibizumab – Lucentis -798

Ranibizumab – Ongavia - (grouped together with the above)

2. For the patients above, how many were new to intra-vitreous treatment? Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept - 1

Bevacizumab - 0

Brolucizumab- 0

Dexamethasone-5

Faricimab-7

Ranibizumab – Lucentis-3

Ranibizumab – Ongavia- (grouped together with the above)

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

FOI/REF FOI-

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust